Objective: To determine whether second whole-brain irradiation is beneficial for patients previously treated with whole-brain irradiation. Methods: A retrospective analysis was done for 31 patients with brain metastases who had undergone re-irradiation. Initial whole-brain irradiation was performed with 30 Gy/10 fractions for 87% of these patients. Whole-brain re-irradiation was performed with 30 Gy/10 fractions for 42% of these patients (3 -40 Gy/1 -20 fractions). Three patients underwent a third wholebrain irradiation. Results: The median interval between the initial irradiation and re-irradiation was 10 months (range: 2 -69 months). The median survival time after re-irradiation was 4 months (range: 1 -21 months). The symptomatic improvement rate after re-irradiation was 68%, and the partial and complete tumor response rate was 55%. Fifty-two percent of the patients developed Grade 1 acute reactions. On magnetic resonance imaging, brain atrophy was observed in 36% of these patients after the initial irradiation and 74% after re-irradiation. Grade 2 encephalopathy or cognitive disturbance was observed in 10 patients (32%) after re-irradiation. Based on univariate analysis, significant factors related to survival after re-irradiation were the location of the primary cancer (P ¼ 0.003) and the Karnofsky performance status at the time of re-irradiation (P ¼ 0.008). A Karnofsky performance status 70 was significant based on multivariate analysis (P ¼ 0.050). Conclusions: Whole-brain re-irradiation for brain metastases placed only a slight burden on patients and was effective for symptomatic improvement. However, their remaining survival time was limited and the incidence of cognitive disturbance was rather high.
INTRODUCTION
The use of stereotactic radiation has become more common as a treatment for metastatic brain tumors. However, wholebrain irradiation remains a standard choice of treatment and is indicated for many patients with these tumors. The treatment strategies for brain metastasis are quite diverse and differ among institutions because of the nature of the disease. In addition, personalized treatment and care should be considered according to each patient's situation. However, in general, for a single metastasis to the brain, intracranial control of disease is improved using a combination of whole-brain irradiation and surgery or stereotactic radiosurgery (SRS) (1, 2) .
For three to four metastases, whole-brain irradiation and SRS are indicated. If the number of lesions exceeds 4, whole-brain irradiation alone is indicated (2, 3) . Whole-brain irradiation is useful for temporary improvement of symptoms as a simple palliative treatment. However, there is a high incidence of relapse and recurrence after whole-brain irradiation. The prognosis is poor with a median survival time of 3 -6 months, and only a small number of patients can attain long-term survival (3) . One treatment approach involves finding a metastasis to the brain using gadoliniumenhanced magnetic resonance imaging (MRI) and repeatedly performing gamma knife radiosurgery rather than wholebrain irradiation. This approach addresses concerns of not only disease control but also chronic toxicity due to whole-brain irradiation (4) .
The majority of the primary cancers are lung cancer, followed by breast cancer and gastrointestinal cancer. In recent years, marked advancements have been made in pharmacotherapy, including molecular-targeted agents, to stabilize extracranial lesions in these diseases. Thus, long-term survival is often achieved, even in cases of advanced or recurrent disease (5 -7). A longer survival time for cancer patients increases the need for retreatment for relapse or recurrence of brain metastasis with whole-brain re-irradiation. However, the dose received from whole-brain re-irradiation may exceed the 'assumed' tolerance dose of the brain; thus, it is necessary to weigh the risks and benefits for these patients. Therefore, some physicians hesitate to offer patients re-irradiation.
The aim of this study was to determine whether or not whole-brain re-irradiation was beneficial by conducting a retrospective analysis of cases from our institution.
PATIENTS AND METHODS

PATIENTS AND TREATMENT
There were 585 adult cancer patients who had undergone whole-brain irradiation for metastatic brain tumors or prophylactic whole-brain irradiation between January 1994 and December 2009 at our institution. The subjects of this study were 31 of these patients who had undergone wholebrain irradiation two or more times due to relapse or recurrence of metastatic brain tumor. Data for the following items were obtained from these patients' medical charts and radiation therapy records for use in this retrospective analysis: location of primary cancer, age, sex, Karnofsky performance status (KPS), status of extracranial lesion, radiation doses (at first irradiation, at second irradiation and later), fractionations, intervals until re-irradiation and other treatments, any symptomatic improvements, tumor response evaluated by MRI, adverse effects and survival time after re-irradiation. Whole-brain irradiation was usually performed five times a week using lateral opposing fields with 6 -18 MV photon beams.
STATISTICAL ANALYSIS
Symptomatic improvement due to re-irradiation was established as at least partial improvement of symptoms. Tumor regression on imaging was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST), and the overall response rate was defined as the sum of the complete response (CR) rate and the partial response rate. The overall survival was determined by the Kaplan -Meier method using the survival time from the day re-irradiation was started until death. Analysis was performed for factors related to the overall survival. A log-rank test was used for univariate analysis and a Cox proportional hazards model was used for multivariate analysis. Brain atrophy was evaluated by comparing pre-and post-irradiation MRI, and obvious enlargement of sulci was used as its indicator. For convenience, the evaluation of toxicity, including changes in the acute phase, was performed using the brain category of the Late Radiation Morbidity Scoring Schema of the Radiation Oncology Group/European Organization for Research and Treatment of Cancer (RTOC/EORTC) Study. A x 2 test was used to compare factors related to toxicity. Statistical analysis was performed using SPSS version 19 (SPSS, Inc., Chicago, IL, USA). A value of P , 0.05 was considered significant. Table 1 shows the characteristics of the 31 patients who were re-irradiated for brain metastases. Their mean age at the time of re-irradiation was 56 years (range: 38 -74 years) and the median KPS was 60 (range: 40 -90). There were 13 females and 18 males. The primary lesion was lung cancer in 26 patients and breast cancer in 5 patients. Histopathology results were adenocarcinoma for 19 patients, small cell Jpn J Clin Oncol 2012;42(4) 265 carcinoma for 11 patients and large cell carcinoma for 1 patient. Eighty-four percent of the patients had extracranial active lesions at the time of re-irradiation. In all cases, progressions of brain metastases were confirmed by MRI studies of the brain after the initial course of whole-brain irradiation. Whole-brain re-irradiation was chosen for the reason that almost all of these patients were noted to have multiple or innumerable brain metastases with symptoms.
RESULTS
The initial whole-brain irradiation was performed with 30 Gy/10 fractions for 87% of the patients (range: 26 -42 Gy/10 -21 fractions). Whole-brain re-irradiation was performed with 30 Gy/10 fractions for 42% of the patients (3 -40 Gy/1 -20 fractions). The median values were the same, but the mean dose for the initial irradiation was 30.6 Gy/10 fractions while that for re-irradiation was lower at 26.5 Gy/ 11 fractions. Two patients underwent re-irradiation for brain metastases that occurred after prophylactic whole-brain irradiation for small cell lung cancer. The conditions of two other patients deteriorated soon after re-irradiation was started. Thus, only one fraction of 3 Gy was given to one of the two patients and 9 Gy/3 fractions were given to the other patient. Partial brain boost irradiation was performed for five patients using 9 -27 Gy/3 -9 fractions. The third whole-brain irradiation was performed with 30 -33.6 Gy/10 -14 fractions for three patients. Seven patients had undergone SRS prior to whole-brain re-irradiation; one patient was treated with SRS after whole-brain re-irradiation. The calculated biological effective dose with an a/b value of 10 (BED 10 ) was 39 for the whole brain using 30 Gy/10 fractions and the BED 2 was 75. The highest BED 10 and BED 2 values were 125 and 228, respectively, including the third whole-brain irradiation.
Chemotherapy was used for 97% of the patients and molecular-targeted agents were used for 29% of the patients over the course of their disease. The median interval between the initial irradiation and re-irradiation was 10 months (range: 2 -69 months), the median survival time after initial diagnosis was 26 months (5 -129 months) and the median survival time after re-irradiation was 4 months (1 -21 months) (Fig. 1) . The rate of symptomatic improvement due to re-irradiation was 68%, and the partial and complete tumor response rate was 55%.
Sixteen patients (52%) had acute reactions to radiation, but these were all mild reactions of Grade 1. Nine patients (29%) experienced headaches, 8 patients (26%) had nausea and a few patients had other minor adverse events (fatigue, dizziness, hiccups and/or redness of scalp). Steroids, mainly dexamethasone, were used for 26 patients (84%) during radiation treatment. Exudative otitis media was seen in seven patients (23%) in the subacute phase.
On MRI, 74% of the patients had brain atrophy after reirradiation, and atrophy was already evident in 36% of the patients after the initial irradiation. Cognitive disturbance or encephalopathy of Grade 2 or higher was seen in 10 patients (32%) during the period of 1 -13 months (median: 3 months) after re-irradiation. However, in most cases, the cognitive disturbance or encephalopathy was judged only from the medical records. Therefore, it was difficult to distinguish encephalopathy related to irradiation from those of other reasons, i.e. deterioration of brain metastases or systemic diseases. The cause of death was neurogenic for 11 patients, of whom 9 had carcinomatous meningitis.
The patient with the longest survival time lived 21 months after whole-brain re-irradiation. This patient had extensivestage small cell lung cancer and attained intracranial CR after initial whole-brain irradiation of 30 Gy/10 fractions. Eleven months later, he received whole-brain re-irradiation of 15 Gy/5 fractions and partial brain boost irradiation of 15 Gy/5 fractions to a large lesion. He once again attained intracranial CR. Fifteen months later, he underwent the third whole-brain irradiation (30 Gy/10 fractions) but eventually died of carcinomatous meningitis. Although brain atrophy was seen after re-irradiation, there was no severe inactive state or cognitive impairment.
Factors related to survival after whole-brain re-irradiation is shown in Table 2 . The following were significant factors related to survival after re-irradiation: location of primary cancer (lung cancer vs. breast cancer, P ¼ 0.003) and KPS at the time of re-irradiation (70 vs. ,70, P ¼ 0.008) based on univariate analysis (Figs 2 and 3) and KPS of 70 (P ¼ 0.050) based on multivariate analysis. There was no significant factor related to cognitive disturbance of Grade 2 or higher.
DISCUSSION
In this study, the median survival time after re-irradiation was 4 months. The rate of symptomatic improvement due to re-irradiation was 68% and the partial and complete tumor response rate was 55%. Whole-brain re-irradiation showed promising effectiveness and placed only a slight burden on patients in the acute phase.
This study involved a retrospective analysis of a small number of cases. Thus, definitive conclusions are difficult to draw. There are concerns of adverse events due to radiation in the subacute and chronic phases. However, whole-brain re-irradiation should be considered for patients suffering from relapse or recurrence with multiple brain metastases and for whom no other treatment is available. If re-irradiation is not performed for these patients, there is a risk for symptomatic exacerbation due to the progression of brain metastases. Whole-brain re-irradiation is useful for symptomatic palliation and may contribute to long-term survival for some patients.
By comparison, another approach involves the control of disease through repeated use of SRS, regardless of the number of brain metastases, and there are some who have raised opposition to whole-brain re-irradiation (4). Their main reason is the neurological and cognitive impairments that can be caused by whole-brain re-irradiation, despite the possibility that this treatment can provide good control of individual lesions. Even initial whole-brain irradiation has some negative effects on neuropsychological function (8) , and it can be speculated that whole-brain re-irradiation will increase the incidence and level of impairment. There are many cases with multiple metastases that are too numerous to treat with SRS. In such cases, whole-brain re-irradiation should be considered apart from meningeal dissemination cases with poor prognosis. However, patients in our study had a limited median survival time of 4 months. It is necessary to use an indicator as a criterion to determine whether the treatment is beneficial to the patients.
In our study, univariate analysis revealed that the origin of primary cancer (P ¼ 0.003) and KPS (P ¼ 0.008) were significant factors related to survival after re-irradiation. The survival time was longer for patients with lung cancer than those with breast cancer and was longer for patients with KPS of 70 or higher than those with KPS ,70. Three of five breast cancer patients underwent re-irradiation for carcinomatous meningitis. For the remaining two breast cancer patients, one had pulmonary lymphangitis carcinomatosa and the other had severe pleural and pericardial dissemination. Thus, there was a bias effect from the time of patient selection. Multivariate analysis revealed that the significant factor was KPS (P ¼ 0.050) alone. Two major previous studies reported that prognostic factors were the absence of extracranial disease, solitary brain metastasis, retreatment dose .20 Gy (9), ECOG performance status, RTOG neurological function class, response to re-irradiation and response to initial brain irradiation (10) . These factors become indicators for the indication of re-irradiation. Table 3 shows major reports on whole-brain re-irradiation (9 -15) . Their results were consistent with ours regarding time until re-irradiation, survival time after re-irradiation and symptomatic improvement. Many reports have supported the use of re-irradiation, although one report concluded that whole-brain re-irradiation was seldom worthwhile (13) . Our study is the first to refer to great lethargy as an impairment due to re-irradiation, and the incidence of brain atrophy was clearly high. It is unclear whether there is a difference between our results and those of other reports regarding the frequency and method of imaging evaluation of brain atrophy. Regarding great lethargy, there was no evidence for brain metastatic tumor exacerbation on imaging. Data were also extracted from the patients' medical records, and it could not be ruled out that some symptoms were due to changes in conditions of the brain metastatic tumors.
One study examined a new option for whole-brain re-irradiation in a few cases. This involved whole-brain irradiation with a multifocal simultaneous integrated boost using helical tomotherapy (16) . This method has the potential to provide better local lesion control while limiting the radiation exposure from whole-brain re-irradiation. Thus, it can be useful for patients who are in good general physical condition. On the other hand, a variety of molecular-targeted agents have been developed in recent years, and their effectiveness against brain metastasis is likely to gradually become more evident. The effectiveness of gefitinib has been reported against brain metastasis and its further development is anticipated (17) .
Whole-brain re-irradiation for brain metastasis places only a slight burden on patients. It is also effective for symptomatic improvement and tumor regression and has resulted in long-term survival for some patients. Although possible remaining survival time is limited in many cases and it is considered as an option, caution is required because this 
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Re-irradiation for metastases with WBRT procedure might cause a high incidence of cognitive disturbance. The risks and benefits for individual patients need to be weighed to determine whether or not whole-brain reirradiation should be used. In addition, the patient's KPS is important in determining the indication. Re-irradiation should be performed only after obtaining informed consent from the patients and their families. The limitations of our study were: (i) no detailed evaluations of neurocognitive functions; (ii) no objective determinations related to the level of impairment; and (iii) no investigations on survival and symptoms that depended on whether or not whole-brain irradiation was performed. To consolidate our study results, it will be necessary to examine whether whole-brain re-irradiation is beneficial by making comparisons with patients who do not undergo this treatment.
